Influence of the dexmedetomidine combined with parecoxib sodium on inflammatory factor, blood gas analysis and stress hormone levels in patients undergoing radical resection of esophageal carcinoma during one lung ventilation

Objective: To investigate the effect of dexmedetomidine combined with parecoxib sodium on the levels of inflammatory factors, blood gas analysis and stress hormone in patients undergoing radical resection of esophageal carcinoma during one lung ventilation. Methods:According to the random data table, 81 cases of esophageal cancer patients were divided into the control group (n=41) and observation group (n=40), the patients in the two groups underwent left thoracotomy esophageal cancer radical resection, the control group patients were treated with parecoxib sodium, and patients in the observation group were treated with parecoxib sodium combined with dexmedetomidine medetomidine treatment, before induction of anesthesia (T0), 30 min of one lung ventilation (T1) and 120 min after operation (T2) at three time points, the levels of inflammatory factors [tumor necrosis factor-α (TNF-α), C reactive protein (CRP)], blood gas analysis[oxygen partial pressure (PaO2), carbon dioxide partial pressure (PaCO2)] and stress hormone[epinephrine (E), norepinephrine (NE)] of the two groups were compared. Results: Intra group level comparison, compared with the levels of two groups at the T0 moment, the levels of TNF-α, CRPand NE of theT1 and T2 moment were significantly increased, the level of PaO2 were significantly decreased, and T2 moment levels were significantly higher than that of T1 moment, the difference was statistical significance;There were no significant differences between the two groups of the levels of TNF-α, CRP, PaO2, E and NE of the T0 moment, the levels of TNF-α, CRP, E and NE of the observation group at the T1 and T2 moment were significantly lower than the control group, at the same time the PaO2 level was significantly higher than the control group, the difference was statistically significant;There were no statistically significant differences in PaCO2 levels between groups and at any time. Conclusion: Dexmedetomidine combined with parecoxib sodium can effectively relieve the inflammatory stress, improve the levels of the blood gas analysis index and stress hormone during one lung ventilation, has an important clinical value.

Clinical analysis of the effect of preemptive analgesia with parecoxib sodium on the corresponding index in cesarean section

Objective:To explore the application of parecoxib preemptive analgesia effect on maternal inflammatory factor, substance P and the stress index in cesarean section.Methods:A total of 84 cases of cesarean section in our hospital from April 2015 to February 2017 were selected and randomly divided into the observation group and the control group with 42 cases each. The observation group received parecoxib sodium before anesthesia induction to 30 min, and control group was given normal saline, respectively. The venous blood samples were collected at the end of the operation, 30 min, 4 h, 8 h and 12 h after operation respectively. The inflammatory factors, P substances and stress indexes were compared between the two groups before and after operation.Results:Substance P in the two groups increased at the end of 30 min after operation, and reached a high peak at 4 h after operation, and then decreased gradually. E (epinephrine) and NE (norepinephrine) reached peak values at 30 min after surgery and then decreased gradually. After the operation, the 30 min, 4 h, postoperative 8 h and postoperative 12 h, P, E and NE indexes in the observation group were lower than those in the control group at the same time point, and the difference was statistically significant. Conclusion: The clinical effect of parecoxib sodium preemptive analgesia in cesarean section is better. It can effectively reduce inflammatory reaction, relieve pain, relieve stress reaction and promote postoperative recovery. It is recommended to be widely used in clinic.

Study on the value of parecoxib sodium preemptive analgesia for laparoscopic surgery based on postoperative pain and stress mediator secretion

Objective:To investigate the effect of parecoxib sodium preemptive analgesia on postoperative pain and stress response in patients with laparoscopic surgery.Methods:118 patients with asymptomatic gallbladder polyps who underwent elective laparoscopic surgery in our hospital between January 2018 and January 2019 were divided into the control group(n=59)and the preemptive analgesia group(n=59)by random number table.Control group received routine total intravenous anesthesia,and preemptive analgesia group received intravenous injection of parecoxib sodium 0.7mg/kg during anesthesia induction.The differences in serum levels of pain mediators[prostaglandin E2(PGE2),substance P(SP)and neuropeptide Y(NPY)],inflammatory factors[interleukin-1β(IL-1β),interleukin-6(IL-6)and interleukin-12(IL-12)]as well as stress mediators[cortisol(Cor),norepinephrine(NE)and epinephrine(E)]at before surgery(T0),30min after extubation(T1),6h after surgery(T2)and 24h after surgery(T3)were compared between the two groups of patients.Results:At T0,there was no significant difference in VAS score as well as inflammatory factor or stress mediator levels between the two groups(P>0.05).At T1,T2 and T3,VAS scores of the preemptive analgesia group were lower than those of the control group;serum IL-1β,IL-6,IL-12 and TNF-αlevels were lower than those of the control group;serum Cor,NE and E levels were lower than those of the control group(P<0.05).Conclusion:Parecoxib sodium preemptive analgesia has a positive effect on reducing postoperative pain and systemic stress in patients with laparoscopic cholecystectomy.

Effect of parecoxib sodium intervention before induction on incision pain and inflammatory stress response after orthopedic surgery

Objective:To study the effect of parecoxib sodium intervention before induction on incision pain and inflammatory stress response after orthopedic surgery.Methods: Patients who underwent orthopedic surgery under lumbar anesthesia combined with epidural block anesthesia in Mianyang Central Hospital between March 2015 and June 2017 were selected and divided into two groups by random number table method, Par group received parecoxib sodium intervention before induction combined with routine postoperative patient-controlled intravenous analgesia, and control group only accepted routine postoperative patient-controlled intravenous analgesia. The pain neurotransmitters, inflammatory molecules and stress molecules in serum and peripheral blood were measured before surgery as well as 1 day and 3 days after surgery.Results: Compared with pain neurotransmitters of same group before surgery, serum PGE2, 5-HT, SP, NPY levels of both groups were significantly lower whereas serum COR and GH levels and peripheral blood JAK2, STAT3, IL-1, IL-6, IFIT1, Nrf2 and HO-1 mRNA expression were significantly higher 1 day and 3 days after surgery, and serum PGE2, 5-HT, SP, NPY, COR and GH levels as well as peripheral blood JAK2, STAT3, IL-1, IL-6, IFIT1, Nrf2 and HO-1 mRNA expression of Par group 1 day and 3 days after surgery were lower than those of control group.Conclusions: Parecoxib sodium intervention before induction can reduce the incision pain and inflammatory stress response after orthopedic surgery.

Analgesic effect of oxycodone combined with parecoxib sodium after laparoscopic cholecystectomy and its influence on inflammatory stress response

Objective: To discuss the analgesic effect of oxycodone combined with parecoxib sodium after laparoscopic cholecystectomy and its influence on inflammatory stress response. Methods:A total of 260 patients with chronic cholecystitis who accepted laparoscopic cholecystectomy in this hospital between December 2016 and May 2017 were divided into control group (n=130) and oxycodone group (n=130) by random number table method. Control group received morphine combined with parecoxib sodium analgesia after operation, and oxycodone group received oxycodone combined with parecoxib sodium analgesia after operation. The differences in serum levels of pain mediators, inflammatory mediators and stress hormones were compared between the two groups immediately after operation (T0), 12 h after operation (T1) and 24 h after operation (T3). Results: At T0, there was no statistically significant difference in serum levels of pain mediators, inflammatory mediators and stress hormones between the two groups. At T1 and T2, serum pain mediators PGE2, NPY, SP and NGF levels of oxycodone group were lower than those of control group whereas β-EP levels were higher than those of control group;serum inflammatory mediators CRP, IL-1β, IL-6 and TNF-αlevels were lower than those of control group;serum stress hormones Cor, NE and INS levels were lower than those of control group. Conclusion: Oxycodone combined with parecoxib sodium analgesia after laparoscopic cholecystectomy can effectively relieve the pain perception and inhibit the systemic inflammatory response and stress response.

Effects of parecoxib sodium intervention before induction on inflammatory stress response and endocrine steady state after laparoscopic surgery

Objective:To study the effects of parecoxib sodium intervention before induction on the inflammatory stress response and endocrine steady state after laparoscopic surgery.Methods:120 cases of patients who accepted laparoscopic cholecystectomy in the Second Affiliated Hospital of Xi'an Medical University between March 2015 and December 2016 were selected and randomly divided into the parecoxib group who accepted parecoxib sodium combined with general anesthesia and the control group who accepted general anesthesia. Before anesthesia induction (T0), immediately after extubation of anesthesia (T1) and 6 hours after extubation (T2), serum levels of inflammatory cytokines and stress hormones as well as peripheral blood levels of immune cells were determined.Results:At T0, serum PGE2, TNF-α, IL-6, CRP, Cor, NE, Ins, C-P and AT-II levels as well as peripheral blood IFNγ+CD4+T cell and Perforin+CD8+T cell levels were not significantly different between two groups of patients;at T1 and T2, serum PGE2, TNF-α, IL-6, CRP, Cor, NE, Ins, C-P and AT-II levels of parecoxib group were significantly lower than those of control group while peripheral blood IFNγ+CD4+T cell and Perforin+CD8+T cell levels were significantly higher than those of control group.Conclusion: Parecoxib sodium intervention before induction can inhibit inflammatory stress response and improve endocrine steady state after laparoscopic surgery.

腰椎间盘突出症经皮椎间孔镜手术麻醉诱导前应用帕瑞昔布钠超前镇痛的临床研究

目的探讨在腰椎间盘突出症经皮椎间孔镜手术麻醉诱导前应用帕瑞昔布钠超前镇痛的临床效果。方法选取70例行经皮椎间孔镜手术治疗的腰椎间盘突出症患者纳入研究,随机分为观察组及对照组,每组35例。对照组予以常规麻醉镇痛,观察组采用帕瑞昔布钠超前镇痛。比较两组患者术中不同时间[切皮时(T1)、分离肌肉韧带时(T2)、对神经根进行刺激时(T3)、缝皮时(T4)]的血流动力学指标[心率(HR)、平均动脉压(MAP)]水平,术后不同时间(术后2、6、12、24 h)的视觉模拟评分法(VAS)评分,术后不良反应发生率。结果两组T2、T3、T4时的HR、MAP水平均低于T1时,且观察组T1、T2、T3、T4时的HR水平分别为(79.63±8.26)、(75.68±7.55)、(72.17±6.49)、(70.04±5.07)次/min,低于对照组的(84.15±8.49)、(80.31±7.44)、(78.65±6.58)、(75.41±6.19)次/min,MAP水平分别为(85.44±10.43)、(77.33±10.12)、(78.65±9.88)、(79.86±9.53)mm Hg(1 mm Hg=0.133 kPa),高于对照组的(79.22±10.66)、(71.51±10.39)、(73.21±8.57)、(74.57±8.46)mm Hg(P<0.05)。观察组术后2、6、12、24 h的VAS评分分别为(2.26±0.46)、(2.86±0.68)、(3.16±0.77)、(3.79±0.94)分,低于对照组的(2.79±0.58)、(3.46±0.79)、(3.76±0.91)、(4.27±0.89)分(P<0.05)。观察组术后不良反应发生率(20.00%)高于对照组(11.43%),但差异无统计学意义(P>0.05)。结论将帕瑞昔布钠超前镇痛应用于腰椎间盘突出症患者经皮椎间孔镜手术麻醉诱导前可改善术中血流动力学,亦能有效降低术后疼痛程度,该方案安全性良好,有利于预后康复。

气相色谱-质谱法测定帕瑞昔布钠中3种硫酸酯类基因毒性杂质

建立气相色谱-质谱法检测帕瑞昔布钠原料药及注射用帕瑞昔布钠中硫酸二甲酯、硫酸二乙酯和硫酸二异丙酯。用Thermo TG-5MS毛细管色谱柱(30 m×0.25 mm,0.25μm)分离,载气为氦气,质谱离子源为电子轰击离子源,采集模式为定时选择性离子监测。3种硫酸酯质量浓度在各自范围内与色谱峰面积线性关系良好,相关系数均大于0.995,平均回收率为95.60%~107.3%,测定结果的相对标准偏差均小于5%(n=6),检出限为20.50~21.88 ng/mL,定量限为61.50~65.64 ng/mL。该法可用于帕瑞昔布钠原料药及注射用帕瑞昔布钠中3种硫酸酯类基因毒性杂质的检测。

帕瑞昔布联合舒芬太尼在腹腔镜肾癌根治术后的镇痛效应及对免疫功能的影响

目的探讨帕瑞昔布联合舒芬太尼在腹腔镜肾癌根治术后镇痛效应及其对免疫功能的影响。方法选取2018年2月至2019年6月收治的行腹腔镜肾癌根治手术治疗的晚期肾癌患者64例,随机分为对照组和研究组,每组32例。研究组于麻醉诱导前30 min静脉注射帕瑞昔布钠,对照组静脉注射0.9%氯化钠溶液,术毕清醒后立即进行舒芬太尼自控镇痛泵。对比2组患者术后镇痛前(T0)及术后镇痛6 h(T1)、12 h(T2)、24 h(T3)及48 h(T4)的视觉模拟(VAS)评分和疼痛分级法(NRS)评分、T0和T4时血流动力学指标[心率(HR)、平均动脉压(MAP)]、T0和T4时免疫功能相关指标[CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)],并记录2组不良反应发生情况。结果VAS评分、NRS评分组间、时间的主效应差异有统计学意义(P<0.05),时间与组间存在交互作用(P<0.05)。T0时2组患者HR、MAP差异无统计学意义(P>0.05),与T0时相比,T4时2组患者HR、MAP均显著降低(P<0.05),且研究组HR、MAP显著低于对照组(P<0.05)。T0时2组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平差异无统计学意义(P>0.05);T4时研究组患者CD3^(+)、CD4^(+)、水平显著高于对照组(P<0.05)。用药后48 h内,2组不良反应发生率比较差异无统计学意义(P>0.05)。结论帕瑞昔布联合舒芬太尼术后镇痛用于腹腔镜肾癌根治术患者,能达到良好的术后镇痛效果,并且能够有效改善患者术后的免疫功能,且安全性更高,值得临床推广。

盐酸羟考酮联合帕瑞昔布钠超前镇痛对妇科腹腔镜手术患者术后疼痛的影响

目的观察盐酸羟考酮联合帕瑞昔布钠超前镇痛对妇科腹腔镜手术患者术后疼痛的影响。方法回顾性分析2021年7月至2023年2月在淮南东方医院集团总医院接受妇科腹腔镜手术患者的临床资料,根据超前镇痛方案不同分为对照组(帕瑞昔布钠)和联合组(盐酸羟考酮联合帕瑞昔布钠)。本研究观察指标包括术后24 h内阿片类药物消耗量、术后0、2、6、12、24 h的视觉模拟评分量表(VAS)评分、自控镇痛泵(PCA)有效按压次数、首次按压PCA时间、补救镇痛次数、镇痛满意度和术后不良反应发生情况。结果研究共纳入患者80例,对照组39例,联合组41例。联合组首次按压镇痛泵时间显著长于对照组(P<0.05),而有效按压次数和舒芬太尼消耗量显著低于对照组(P<0.05)。两组补救镇痛人数比较差异无统计学意义(P>0.05)。联合组术后0、2、6 h的VAS评分显著低于对照组(P<0.05),术后12 h和24 h的VAS评分与对照组比较差异无统计学意义(P>0.05)。联合组患者镇痛满意度评分显著高于对照组(P<0.05),不良反应发生率两组比较差异无统计学意义(P>0.05)。结论盐酸羟考酮联合帕瑞昔布钠的超前镇痛方案显著降低了妇科腹腔镜术后患者阿片类药物消耗量,减轻患者术后疼痛,提升患者满意度。

帕瑞昔布钠合成工艺的改进

以5-甲基-3,4-二苯基异噁唑起始物料,经氯磺化、氨化、丙酰化、成盐等4步制得帕瑞昔布钠,总收率66.7%。产品结构经质谱、核磁确证。此工艺原料廉价易得,成本较低,适合工业化生产要求。

帕瑞昔布钠杂质的合成

为有效控制帕瑞昔布钠原料药质量并建立质量标准,以2-溴苯基丙酮为起始原料,与四氢吡咯缩合后,经环合、脱去四氢吡咯、偶联、氧化、成磺酰胺、与丙酸酐缩合制得帕瑞昔布钠杂质N-((2-(5-甲基-3-苯基异恶唑-4-基)苯基)磺酰基)丙酰胺(9),并对其合成工艺进行了优化。优化条件后,杂质总收率为42.8%(以2-溴苯基丙酮计),纯度达99.0%(HPLC)。其结构经核磁、质谱确证。合成工艺合理可行、反应条件温和,制备的杂质纯度高,可作为帕瑞昔布钠药物质量控制的杂质对照品。

帕瑞昔布联合羟考酮在股骨转子间骨折手术患者中的镇痛效果

目的 观察帕瑞昔布钠联合盐酸羟考酮在股骨转子间骨折手术患者中的镇痛效果。方法 回顾性分析杭州市第九人民医院骨科收治的122例股骨转子间骨折手术患者(2020年1月至2024年3月)临床资料。根据患者镇痛方法不同分为对照组和观察组,两组各61例患者,对照组患者采取帕瑞昔布钠镇痛,观察组患者采取帕瑞昔布钠联合盐酸羟考酮镇痛,对比两组患者术后6、12、24 h视觉模拟疼痛评分法(VAS)评分及Ramsay镇静评分(RASS)、术后12 h两组患者肾上腺素(AD)与去甲肾上腺素(NE)等应激指标、不良反应。结果 术后6、12、24 h,观察组患者的VAS评分分别为(2.85±0.73)分、(1.89±0.44)分、(0.85±0.19)分,均分别低于对照组患者(3.25±0.23)分、(2.52±0.37)分、(1.58±0.27)分,t=4.082、8.559、17.269,均P<0.001;术后6、12、24 h,观察组患者RASS评分分别为(3.10±0.11)分、(2.79±0.25)分、(2.11±0.24)分,均高于对照组患者各项评分(2.22±0.63)分、(1.86±0.30)分、(1.71±0.14)分,t=10.747、18.600、11.244,均P<0.001;术后12 h观察组患者的AD及NE水平分别为(92.65±6.93) pg·mL^(-1)、(612.94±10.34) pg·mL^(-1),均低于对照组患者(100.54±7.23) pg·mL^(-1)、(644.62±9.52) pg·mL^(-1),t=6.153、17.604,均P<0.001;观察组与对照组不良反应率分别为4.92%、1.64%,均较低,χ^(2)=1.034,P>0.05。结论 帕瑞昔布钠联合盐酸羟考酮在股骨转子间骨折手术患者中镇痛效果良好,可较好地改善患者疼痛程度及应激反应,不良反应较少。

氢吗啡酮联合帕瑞昔布钠对合并冠心病行非心脏胸部手术患者镇痛效果的影响

目的 探讨氢吗啡酮联合帕瑞昔布钠对合并冠心病行非心脏胸部手术患者镇痛效果的影响。方法 选取2020年9月至2022年9月浙江中医药大学附属杭州市中医院138例合并冠心病行非心脏手术患者,按照随机数字表法将其分为A组、B组、C组,各46例。三组均在全麻下进行手术,A组给予氢吗啡酮+帕瑞昔布钠,B组给予帕瑞昔布钠,C组给予氢吗啡酮。比较三组拔管前5 min(T_(0))、拔管即刻(T_(1))、拔管后5 min(T_(2))、拔管后10 min(T_(3))平均动脉压(MAP)、心率(HR)、呼吸频率(RR);比较三组术后4、12、24、72 h咳嗽时、静息时视觉模拟评分法(VAS)评分;比较三组术后24 h患者自控静脉镇痛(PCIA)有效按压次数;比较三组术前、术后12 h、术后72 h前列腺素E_(2)(PGE_(2))、神经肽Y(NPY)、肾上腺皮质激素(ACTH)、醛固酮(ALD)、C-肽(C-P);记录不良反应发生情况。结果 整体比较:三组MAP、HR、RR组间、时间、交互作用比较,差异有统计学意义(P<0.05)。进一步两两比较,组内比较:T_(1)~T_(3)时,三组MAP、HR高于T_(0)时,RR低于T_(0)时,差异有统计学意义(P<0.05)。组间比较:T_(1)~T_(3)时,A组MAP、HR低于B、C组,RR高于B、C组,差异有统计学意义(P<0.05)。整体比较:三组咳嗽时、静息时VAS评分组间、时间、交互作用比较,差异有统计学意义(P<0.05);进一步两两比较,组内比较:术后12、48、72 h,三组咳嗽时、静息时VAS评分低于术后4 h,差异有统计学意义(P<0.05);组间比较:术后4、12 h,A组咳嗽时、静息时VAS评分低于B、C组,差异有统计学意义(P<0.05)。A组术后24 h PCIA有效按压次数低于B组、C组,差异有统计学意义(P<0.05)。整体比较:三组PGE_(2)、NPY、ALD、C-P、ACTH水平组间、时间、交互作用比较,差异有统计学意义(P<0.05);进一步两两比较,组内比较:术后12 h,三组PGE_(2)、NPY、ALD、C-P、ACTH水平高于术前,差异有统计学意义(P<0.05);组间比较:术后12 h,A组PGE_(2)、NPY、ALD、C-P、ACTH水平低于B、C组,差异有统计学意义(P<0.05)。A组与B组不良反应总发生率比较,差异无统计学意义(P>0.05);A组与C组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 氢吗啡酮联合帕瑞昔布钠可缓解合并冠心病行非心脏手术患者术后疼痛感,调节内分泌、循环功能,且安全性高。

帕瑞昔布钠联合右美托咪定对甲状腺全麻手术患者炎性因子水平及应激反应的影响

目的探讨帕瑞昔布钠联合右美托咪定对甲状腺全麻手术患者炎性因子水平及应激反应的影响。方法选取2020年4月至2022年4月我院接受甲状腺全麻手术的88例患者作为研究对象,采用随机数字表法将其分为A组和B组,各44例。A组给予右美托咪定,B组给予帕瑞昔布钠联合右美托咪定。比较两组的麻醉效果。结果术前,两组的肿瘤坏死因子-α(TNF-α)、P物质(SP)及白细胞介素-6(IL-6)水平比较,差异无统计学意义(P>0.05);术后,B组的TNF-α、SP及IL-6水平均低于A组,差异具有统计学意义(P<0.05)。两组的去甲肾上腺素(NE)、肾上腺素(A)水平在麻醉诱导给药后5 min(T2)下降,插管前(T3)上升,插管后即刻(T4)又下降,B组的NE、A水平变化幅度小于A组。B组的不良反应总发生率为11.36%,显著低于A组的29.55%,差异具有统计学意义(P<0.05)。结论帕瑞昔布钠联合右美托咪定可有效抑制甲状腺全麻手术患者的炎性因子释放,减轻应激反应,且安全性较好。

右美托咪定复合帕瑞昔布钠对胸腔镜肺癌根治术单肺通气患者炎症因子水平及肺氧合的影响

目的:探讨右美托咪定复合帕瑞昔布钠对胸腔镜肺癌根治术单肺通气患者炎症因子水平及肺氧合的影响。方法:选取2021年1月—2023年1月海安市中医院收治的胸腔镜肺癌根治术单肺通气患者192例,采用随机数字表法分为三组,其中右美托咪定组(n=58)于麻醉诱导前20 min静脉滴注1μg/kg右美托咪定,之后以0.6μg/(kg·h)维持剂量输注至关胸,帕瑞昔布钠组(n=58)于麻醉诱导前20 min静脉滴注帕瑞昔布钠40 mg,复合组(n=76)给予右美托咪定复合帕瑞昔布钠静脉滴注。比较三组不同时间点炎症因子、肺氧合指标水平及疼痛程度,并记录三组不良反应发生情况。结果:单肺通气30 min(T_(1))、术毕(T_(2)),三组血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平均较麻醉诱导前(T0)升高,差异均有统计学意义(P<0.05),但复合组T_(1)、T_(2)上述各项指标均低于右美托咪定组和帕瑞昔布钠组,差异均有统计学意义(P<0.05);T_(1)、T_(2),右美托咪定组和帕瑞昔布钠组上述各项指标比较,差异均无统计学意义(P>0.05)。T_(1)、T_(2),三组动脉血氧分压(PaO_(2))、氧合指数(OI)水平均较T0降低,二氧化碳分压(PaCO_(2))水平均较T0升高,差异均有统计学意义(P<0.05),但复合组T_(1)、T_(2)的PaO_(2)、OI均高于右美托咪定组和帕瑞昔布钠组,PaCO_(2)水平均低于右美托咪定组和帕瑞昔布钠组,差异均有统计学意义(P<0.05);T_(1)、T_(2),右美托咪定组和帕瑞昔布钠组上述各项指标比较,差异均无统计学意义(P>0.05)。术后2、6、24 h,复合组VAS评分均低于右美托咪定组和帕瑞昔布钠组,差异均有统计学意义(P<0.05);右美托咪定组和帕瑞昔布钠组各时间点VAS评分比较,差异均无统计学意义(P>0.05)。三组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:右美托咪定复合帕瑞昔布钠可减轻胸腔镜肺癌根治术单肺通气患者炎症因子水平及术后疼痛程度,对患者肺氧合功能影响小。

我院注射用帕瑞昔布钠临床应用的干预效果分析

目的探讨多部门联合监督管理对我院注射用帕瑞昔布钠临床使用的综合干预效果,促进临床合理用药。方法药学部门联合医务部、质控部等部门,制定本院注射用帕瑞昔布钠评价标准,建立药学干预与职能部门监督管理互相配合的干预模式。选取2021年1~10月(干预前)及2021年11月~2022年8月(干预后)使用注射用帕瑞昔布钠的住院患者病历127份,回顾性分析干预前和干预后注射用帕瑞昔布钠的临床使用情况及合理用药情况。结果干预前注射用帕瑞昔布钠的用药不合理率为70.00%,主要表现为给药疗程不合理,适应证不合理和禁忌证给药;干预后注射用帕瑞昔布钠的用药不合理率为29.85%,明显下降,主要表现在给药疗程不合理,但超疗程用药天数明显下降,P<0.05,有统计学意义。干预后注射用帕瑞昔布钠临床使用量较干预前明显下降,重点科室使用数量也明显下降。结论多部门联合干预注射用帕瑞昔布钠的临床使用,降低了用药不合理率,降低了药品临床使用量,这一干预模式可推广应用到其他药品临床使用的管理。

帕瑞昔布钠超前镇痛联合术后舒芬太尼静脉自控镇痛在下肢骨折手术患者中的应用效果

目的:观察帕瑞昔布钠超前镇痛联合术后舒芬太尼静脉自控镇痛在下肢骨折手术患者中的应用效果。方法:回顾性分析2022年7月至2023年5月该院收治的60例下肢骨折手术患者的临床资料,按不同镇痛方案将其分为对照组与观察组各30例。两组均进行全身麻醉,在此基础上,对照组术后予以枸橼酸舒芬太尼注射液静脉自控镇痛,观察组在对照组基础上联合帕瑞昔布钠超前镇痛。比较两组麻醉相关指标(麻醉苏醒时间、拔管时间、意识恢复时间),术后疼痛程度[视觉模拟评分法(VAS)]评分、苏醒期躁动[Riker镇静和躁动(SAS)]评分、手术前后应激指标[皮质醇(Cor)、去甲肾上腺素(NE)]水平和不良反应发生率。结果:两组麻醉苏醒时间、拔管时间、意识恢复时间比较,差异均无统计学意义(P>0.05);术后6、12、24、48 h,观察组VAS评分均低于对照组,差异有统计学意义(P<0.05);观察组苏醒期SAS评分低于对照组,差异有统计学意义(P<0.05);术后24 h,两组Cor、NE水平均高于治疗前,但观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:帕瑞昔布钠超前镇痛联合术后舒芬太尼静脉自控镇痛应用于下肢骨折手术患者可降低苏醒期SAS评分和应激指标水平,其效果优于单纯术后舒芬太尼静脉自控镇痛。

Effects of parecoxib + dexmedetomidine on systemic inflammation and oxidative stress during anesthesia recovery period of thoracoscopic surgery

Objective: To study the effects of parecoxib + dexmedetomidine on systemic inflammation and oxidative stress during anesthesia recovery period of thoracoscopic surgery. Methods:The lung cancer patients undergoing thoracoscopic surgery in Kailuan General Hospital between March 2015 and February 2018 were selected as the research subjects and randomly divided into the experimental group who received parecoxib + dexmedetomidine preemptive analgesia combined with conventional anesthesia and the control group who received conventional anesthesia. 3 and 5 d after surgery, serum was collected to measure the contents of inflammatory cytokines interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-18 (IL-18), intercellular adhesion molecule-1 (ICAM1) and monocyte chemoattractant protein-1 (MCP1) as well as oxidative stress mediators cortisol (COR), malondialdehyde (MDA), endothelin-1 (ET-1), superoxide dismutase (SOD) and total antioxidant capacity (T-AOC), and peripheral anticoagulant blood was collected to measure the expressions of inflammatory signaling molecules Toll-like receptor 4 (TLR4), NOD-like receptor protein 3 (NLRP3), nuclear factor-κB (NF-κB), apoptosis-associated speck-like protein containing CARD (ASC) and cysteinyl aspartate specific proteinase-1 (caspase-1) as well as oxidative stress molecules nuclear factor E2-related factor 2 (NRF2), antioxidant response element (ARE), NADPH oxidase (NOX) 2 and NOX4. Results: 3 and 5 d after surgery, serum IFN-γ, IL-1β, IL-18, ICAM1, MCP1, COR, MDA and ET-1 contents as well as peripheral blood TLR4, NLRP3, NF-κB, ASC, Caspase-1, NRF2, ARE, NOX2 and NOX4 expression intensity of the experimental group were significantly lower than those of the control group whereas serum SOD and T-AOC contents were higher than those of the control group. Conclusion: Parecoxib+ dexmedetomidine can inhibit the systemic inflammation and oxidative stress during anesthesia recovery period of thoracoscopic surgery.

超声引导下颈浅丛神经阻滞联合帕瑞昔布钠对全麻甲状腺手术患者术后镇痛及炎性反应的影响

目的探讨超声引导下颈浅丛神经阻滞联合帕瑞昔布钠对全麻甲状腺手术患者术后镇痛、炎性反应的影响。方法选择扬州市江都人民医院2020年1—12月期间收治的60例甲状腺择期手术患者作为研究对象,按随机数表法分为对照组和观察组,各30例。对照组在麻醉诱导前进行超声引导下颈浅丛神经阻滞,观察组在颈浅丛神经阻滞成功后加用帕瑞昔布钠。记录并比较术后2 h(T1)、术后6 h(T2)、术后12 h(T3)、术后24 h(T4)、术后48 h(T5)疼痛评分,术前24 h(T0)、T4时点炎性反应指标,以及不良反应情况。结果T1~T4时,观察组VAS评分[(2.76±0.72)分、(2.33±0.47)分、(2.43±0.50)分、(1.56±0.50)分]均低于对照组,差异有统计学意义(t=-2.936、-8.847、-5.605、-2.497,P<0.05);但T5时两组VAS评分比较,差异无统计学意义(P>0.05)。T0时两组IL-6、CRP、TNF-α水平比较,差异无统计学意义(P>0.05);T4时观察组IL-6、CRP、TNF-α水平[(59.20±5.07)pg/mL、(16.56±3.09)mg/L、(30.70±3.89)pg/mL]均低于对照组,差异有统计学意义(t=-5.773、-5.202、-10.056,P<0.001)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论超声引导下颈浅丛神经阻滞联合帕瑞昔布钠可以巩固全麻甲状腺手术的术后疼痛,减轻炎性反应,安全性高。